Isavuconazole
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Isavuconazole |
| DrugBank ID | DB11633 |
| Brand Names (EU) | Cresemba |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.99% |
Approved Indication (EMA)
Powder for concentrate for solution for infusion: Cresemba is indicated in patients from 1 year of age and older for the treatment of invasive aspergillosis mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Hard capsules: Cresemba hard capsules are indicated in adults and in paediatric patients from 6 years of age for the treatment of invasive aspergillosi
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 98.99% | DL |
| 2 | migraine with brainstem aura | 98.79% | DL |
| 3 | migraine with or without aura, susceptibility to | 98.31% | DL |
| 4 | pulmonary hypertension | 98.13% | DL |
| 5 | kyphoscoliotic heart disease | 97.98% | DL |
| 6 | rheumatoid arthritis | 97.57% | DL |
| 7 | atrophoderma vermiculata | 97.39% | DL |
| 8 | nephrogenic syndrome of inappropriate antidiuresis | 97.29% | DL |
| 9 | Prinzmetal angina | 97.08% | DL |
| 10 | ulerythema ophryogenesis | 97.01% | DL |
| 11 | brachydactyly-syndactyly syndrome | 96.49% | DL |
| 12 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 96.03% | DL |
| 13 | tendinitis | 95.04% | DL |
| 14 | homozygous familial hypercholesterolemia | 94.97% | DL |
| 15 | thrombotic disease | 94.89% | DL |
| 16 | idiopathic granulomatous myositis | 94.83% | DL |
| 17 | myositis fibrosa | 94.83% | DL |
| 18 | multiple endocrine neoplasia | 94.73% | DL |
| 19 | hyperthyroidism | 94.57% | DL |
| 20 | cor pulmonale | 94.49% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.